S2302 Pragmatica-Lung is a federally-funded, streamlined clinical trial examining a new combination of agents in patients with advanced non-small cell lung cancer (NSCLC). Like most studies, it is focused on improving outcomes for patients with cancer—but it is also poised to simplify and transform the entire clinical trials model as we know it.
Steady advancements in cancer treatments over the past century have led to significant improvements in the expected lifespan of cancer patients. However, to this day, cancer is very rarely cured.
At the 2022 annual meeting of the Association of American Cancer Institutes—hosted by The University of Kansas, the newest NCI-designated Comprehensive Cancer Center—Dr. Doug Lowy, then acting NCI director, discussed how enhancing the way centers communicate research is vital to the eradication of cancer.
I read with interest the recently published story on the recommendations to streamline data collection in certain NCI trials presented at the Nov. 9, 2022, meeting of the Clinical and Translational Research Committee (The Cancer Letter, Nov. 11, 2022).
Smoking is still the number one preventable cause of death in the U.S. and lung cancer is far and away the number one cause of cancer death in the U.S.
To understand the state of affairs with electronic nicotine delivery systems (ENDS), you have to go back to 2006, when ENDS, such as e-cigarettes, became widely available.
Yuliia’s phone rings. She shows me the app warning of an imminent missile strike in her district in Ukraine, grateful that she does not need to respond—for the time being she is safe in the USA.
Earlier this week, The New England Journal of Medicine published the first results of the Pragmatic Nordic-European Initiative on Colorectal Cancer (NordICC) Trial of Colonoscopy, which was conducted in Poland, Norway, Sweden, and the Netherlands to measure the efficacy of colonoscopy in reducing colorectal cancer incidence and mortality.
“Doc, should I cancel my colonoscopy?”
The unprovoked war in Ukraine has raised increasing concerns of a nuclear escalation.
